Table 2 Clinical and laboratory parameters of the limited-1 and limited-2 subgroups
Clinical feature | Limited 1 (n = 10) | Limited 2 (n = 5) | |
|---|---|---|---|
MRSS, median (range) | 5.5 (3–10) | 6 (5 − 7) | |
Disease duration from first non-Raynaud’s symptom, median (range) years | 16 (4–40) | 6 (2–28) | |
ANA primary pattern, N (%) patients | Homogenous | 3 (30) | 1 (20) |
Speckled | 1 (10) | 1 (20) | |
Centromere | 5 (50) | 1 (20) | |
Nucleolar | 0 | 1 (20) | |
SSc-specific antibodies | Scl-70 | 3 (30) | 1 (10) |
RNA pol III | 0 | 0 | |
Vasculopathy, N (%) patients | Digital ulcers | 4 (40) | 2 (40) |
PAH | 0 | 0 | |
Renal crisis | 0 | 0 | |
Interstitial lung disease, N (%) | 2 (20) | 2 (40) | |
Inflammatory arthritis, N (%) | 3 (30) | 0 | |
Vascular therapies, N (%) patients | ARB | 8 (80) | 2 (40) |
Ca channel antagonist | 2 (20) | 2 (40) | |
Iloprost | 3 (30) | 1 (20) | |
PDE5 inhibitor | 1 (10) | 2 (40) | |
Immunosuppressive therapies, N (%) patients | PDN | 2 (20) | 2 (40) |
MMF | 2 (20) | 1 (20) | |
MTX | 2 (20) | 0 | |
AZA | 1 (10) | 0 | |
HCQ | 2 (20) | 1 (20) | |